Highly regulated, with strict compliance rules, work can be in-house or in collaboration with another entity. Guidance includes practice notes on UK and EU regime for clinical trials and various precedents.
Patents and supplementary protection certificates are significant to many life sciences businesses. We have practice notes on pharmaceutical patents, biotechnology patents, IP protection for medical devices and more.
This content includes guidance on marketing authorisations, orphan and paediatric medicines, pharmacovigilance, manufacturing, unlicensed and off-label medicines.
Covering key areas of medical devices regulation including classification, conformity assessments, clinical and performance evaluation as well as post-market surveillance.
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that the government has tabled amendments to the Health Bill to support...
This week's edition of Life Sciences weekly highlights includes news that the MHRA has tabled three amendments to the Health Bill aimed at modernising...
The European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) have published a draft data standards framework for consultation. The...
The National Institute for Health and Care Excellence (NICE) has confirmed that it will adopt the UK EQ-5D-5L value set for measuring health-related...
The Medicines and Healthcare products Regulatory Agency (MHRA) has updated its pharmacovigilance procedures guidance with new information on periodic...
This Practice Note is intended to be used for horizon scanning purposes to track the progress of key UK regulatory and legal developments in relation...
No medicinal product may be placed on the market without having first obtained an approval known as a marketing authorisation (MA). The MA sets out...
This Practice Note provides further guidance on key definitions used in the United Kingdom General Data Protection Regulation, Assimilated Regulation...
This Practice Note is a ‘how to’ guide on reviewing an NDA (also known as a non-disclosure agreement or a confidentiality agreement) which signposts...
A ‘patent’ is a document conferring so-called monopoly rights to an inventor. A patent protects new inventions and may cover aspects such as how...
This Agreement is made on [date]Parties1[insert name of Party A][ of OR a company incorporated in [England and Wales] under number [insert registered...
This training presentation introduces the law of trade marks and is aimed at non-specialists. It deals with protection and enforcement of UK trade...
Parties1[Insert the company name (the name of the sponsor)] with a registered office at [insert address] hereinafter referred to as the Controller;...
This Agreement is made on [insert date]parties1[insert name of customer ][of OR a company incorporated in [England and Wales] under number [insert...
This Agreement is made on [insert date]parties1[insert name of manufacturer ][of OR a company incorporated in [England and Wales] under number [insert...
Introduction to technology transfer agreements in the Life Sciences industryWhat is a technology transfer agreement?The term ‘technology transfer...
Regulation of cosmetic products in the UKThis Practice Note provides an overview of the UK regulatory framework for cosmetics. It sets out the legal...
Intellectual property protection for medical devicesChanges to intellectual property (IP) law from 1 January 2021Before discussing how intellectual...
Second and subsequent medical use patent claimsBackground to medical use claimsSecond (and subsequent) medical use patent claims are specific to the...
The experimental use and Bolar-type exemptions to patent infringementPatent systems are intended to foster innovation, not to impede it. For this...
The PMCPA has recently launched a consultation to update:•the 2021 ABPI Code of Practice•the Constitution and Procedure which sets out how the PMCPA...
Clinical Research Organisation (CRO) master services agreementDATA PROTECTION NOTICE: Please note that the drafting of clause 7 (Data Protection), in...
The EU Clinical Trials RegulationThis Practice Note looks at Regulation (EU) 536/2014, the EU Clinical Trials Regulation (CTR), which governs clinical...
Medical devices due diligence questionnaireIntroductionThis medical devices regulatory due diligence questionnaire relates to the proposed purchase by...
Biotechnology patentsPatenting biotechnological inventionsBiotechnological inventions are, in principle, patentable. While there is no general...
Unlicensed medicinal products and off-label use of medicinal productsThis Practice Note explores unlicensed medicinal products and the various ways...
The Medicines and Healthcare products Regulatory Agency (MHRA) has released guidance on the implementation of changes to pharmacovigilance for...
The regulation of medical devices in the UKThis Practice Note provides an overview of the UK regulatory regime for medical devices. It explains the...
The National Archives has published the judgment in British Standards Institution v RRR Manufacturing Pty Ltd, R (on the application of) [2024] EWCA...
The Competition and Markets Authority (CMA) has announced a Phase 1 merger inquiry into Roche Diagnostics Ltd's acquisition of point-of-care testing...
The Department for Science, Innovation and Technology (DSIT) has released the interim International Scientific Report on the Safety of Advanced...
The regulation of advanced therapy medicinal productsThe development of medicine, biomicrobiology and biotechnology has led to the emergence of a...
A medicinal product which contains the same active substances and has the same pharmaceutical form as the original branded reference medicinal product, and whose bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies, as defined in Article 10(2)(b) of Directive 2001/83/EC.
The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem.
Refers to the data exclusivity period granted by Article 10(1) of Directive 2001/83/EC, in which pre-clinical and clinical trial data generated and used to support the authorisation of an innovative medicinal product cannot be referred to by an applicant for a marketing authorisation for a generic product.